论文部分内容阅读
本文介绍了免疫性流产患者在免疫治疗后的反应。我们对75例流产3次或以上的妇女进行了配偶白细胞免疫治疗。在治疗前后分别采用液流细胞仪(FCM)和传统的微量淋巴毒试验(MCX)测定血清抗白细胞抗体,并以混合淋巴细胞培养(MLC)测定其血清抑制效应。结果表明免疫治疗后多数患者能产生抗白细胞抗体和MLC抑制效应,提示免疫治疗可促使机体产生封闭性抗体以增强免疫保护作用。我们对其中22例并测定了治疗前后对非配偶白细胞的抗体反应,发现多数患者FCM阳性,部分MCX阳性。提示这种抗体并非针对个体特异性MHC Ⅰ型或Ⅱ型抗原,抗体对配偶及非配偶白细胞的反应并不能单纯以具有相同的HLA抗原来解释。实验表明FCM法敏感性高,能准确、快速地检出抗体,明显优于MCX与MLC。
This article describes the response of immunocompromised patients after immunotherapy. We administered splenic leukocyte immunotherapy to 75 women who have had 3 or more abortions. Serum anti-leucocyte antibodies were measured by flow cytometry (FCM) and traditional lymphocytotoxicity assay (MCX) before and after treatment, and their serum inhibitory effects were measured by mixed lymphocyte culture (MLC). The results show that most patients after immunotherapy can produce anti-leucocyte antibodies and MLC inhibitory effect, suggesting that immunotherapy can cause the body to produce a closed antibody to enhance the protective effect of immunity. In 22 of them, we measured the antibody response to non-spleen leucocytes before and after treatment. Most of the patients were positive for FCM and some were positive for MCX. Suggesting that this antibody is not directed at individual-specific MHC class I or type II antigens, the antibody response to spouses and non-spouse white blood cells and can not be simply to have the same HLA antigen to explain. Experiments show that the FCM method is highly sensitive, accurate and rapid detection of antibodies, significantly better than MCX and MLC.